Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[haysaw]

This was also discussed two months ago in #msg-103262093, and no reasonable explanation was provided. Do they think that parsing out the indications is a better way to leverage the assets? In a perfect world, or with a highly sought and valued asset, maybe. But there is too much risk at losing it all right now. They need to go after the primary benefit, anti-inflammation, and stop playing games by going after the byproducts of the disease. I would gather the anti-inflammatory market is a multibillion dollar business, so they should quit f#cking around with the fancy leverage game. Why? Because now, they have zero leverage. And without the supplement, less than zero.

Dr. Mullen:

You need to hit this head on and in a linear fashion. Go after the primary target, inflammation.

You also need to get the supplement back on the market. Give the people what they want (as opposed to taking it away), and as the science progresses (favorably, hopefully), the revenue will flood in. It's been built, so let them come. Don't tear it down unnecessarily. There are thousands and thousands of supplements out there with much less corroboratory evidence, don't get dragged down by a flawed FDA system. If it works, fight for its existence, period!